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Abstract
Vision loss, among the most feared complications of diabetes, is primarily caused by diabetic
retinopathy, a disease that manifests in well-recognized, characteristic microvascular lesions.
The reasons for retinal susceptibility to damage in diabetes are unclear, especially considering
that microvascular networks are found in all tissues. However, the unique metabolic demands
of retinal neurons could account for their vulnerability in diabetes. Photoreceptors are the first
neurons in the visual circuit and are also the most energy-demanding cells of the retina. Here,
we review experimental and clinical evidence linking photoreceptors to the development of
diabetic retinopathy. We then describe the influence of retinal illumination on photoreceptor
metabolism, effects of light modulation on the severity of diabetic retinopathy, and recent
clinical trials testing the treatment of diabetic retinopathy with interventions that impact
photoreceptor metabolism. Finally, we introduce several possible mechanisms that could link
photoreceptor responses to light and the development of retinal vascular disease in diabetes.
Collectively, these concepts form the basis for a growing body of investigative efforts aimed at
developing novel pharmacologic and nonpharmacologic tools that target photoreceptor physiology to treat a very common cause of blindness across the world.

Introduction
Diabetic retinopathy (DR) is a leading cause of acquired blindness, but its pathogenesis requires
clarification. Although it ultimately manifests as a characteristic microvasculopathy, DR is
associated with abnormalities of many retinal cell types preceding the onset of microvascular
deterioration (Honasoge et al., 2019). In fact, the photoreceptor—the first cell of the visual
circuit—is an important contributor to retinal vascular disease in diabetes (Liu et al., 2016). The
retina’s remarkable metabolic signature could underlie its exceptional vulnerability to damage
from the metabolic perturbation caused by diabetes (Antonetti et al., 2006), and photoreceptors
are the most metabolically demanding cells in the retina (Wong-Riley, 2010) making them a
prime target of early disease. Furthermore, since illumination of the retina determines the energy
expenditure of photoreceptors, light exposure itself may influence the pathogenesis and course
of retinal diseases, such as DR (Arden et al., 2005). Therefore, light-dependent modulation of
photoreceptor physiology in early diabetes has been a considerable focus of study. In this review,
we will briefly discuss the formative evidence implicating photoreceptor physiology in the
development of DR. Next, we will address how these early observations combined with lightdependent effects on photoreceptor metabolism gave rise to the hypothesis that light exposure
could modulate the pathogenesis of this disease. Finally, we will describe the studies designed to
test this hypothesis and introduce a variety of mechanistic possibilities arising from their
findings.
Photoreceptor dysfunction in diabetes
Clinical evidence
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The strongest evidence for photoreceptor involvement in DR comes from clinical observations.
First, elevated levels of a photoreceptor-secreted protein—retinol-binding protein 3 (RBP3)—
are linked to protection from DR, as reported by investigators at the Joslin Diabetes Center who
participated in the MEDALIST trial, a study of patients with diabetes who survived with 50 years
or more of disease. The protective effects of RBP3 were also seen in overexpression studies using
a common mouse model of diabetes. Although RBP3 is an integral protein in the retinoid cycle,
its mechanism of action in DR could be related to direct binding and negative regulation of
GLUT1 transporter—the major glucose transporter in the retina (Yokomizo et al., 2019).
Second, patients with diabetes show electrophysiological signs of photoreceptor dysfunction.
In a small but seminal electroretinography study by Holopigian and colleagues, diabetes was
associated with reduced photoreceptor a-wave sensitivity, consistent with altered photoreceptor
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transduction (Holopigian et al., 1997). More recently, McAnany and
Park intricately dissected temporal features of the light-adapted
flicker electroretinogram to provide additional evidence that diabetes likely impacts photoreceptor physiology (McAnany & Park,
2019). In addition, Holopigian and colleagues also identified
diabetes-associated abnormalities of b-wave amplitude and implicit
time, primarily generated by ON-bipolar cells, which may represent
the effects of photoreceptor dysfunction on downstream signaling at
bipolar cells (Holopigian et al., 1997). Using full-field electroretinography, Bresnick and colleagues demonstrated that a-wave implicit
times were significantly delayed in 72 patients with diabetes compared to 29 healthy controls (Bresnick & Palta, 1987). Thus, patients
with DR present with electrophysiological deficits in photoreceptor
responses at both the receptoral and postreceptoral levels. Further
evidence for abnormalities of outer retinal function in patients with
diabetes comes from studies of photostress recovery, in which
diabetes is associated with slower rates of photopigment regeneration after bleaching (Elsner et al., 1987). Whether these electrophysiological changes represent primary insults to the photoreceptor due
to diabetes or whether they represent a consequence of early capillary
damage remains unclear. This issue is made more complex by recent
findings using high-resolution optical coherence tomography and
optical coherence tomography angiography in which diabetes is
associated with deep capillary plexus abnormalities and outer retinal
structural changes, even in the absence of macular edema (Scarinci
et al., 2015; 2016).
Finally, patients with coexisting diabetes and outer retinal
degenerative disorders such as retinitis pigmentosa (RP) tend to
be spared from severe DR. For example, Sternberg and colleagues
noted a negative correlation between RP and the severity of DR
(Sternberg et al., 1984). The late electrophysiologist Dr. Geoffrey
Arden reported in a survey of 55 patients with RP and diabetes
(with mean duration of diabetes of ~40 years) that none had clinical
DR, although many had nonretinal microvascular complications of
diabetes (Arden, 2001). These findings formed the basis for Arden’s
hypothesis that the absence of metabolically demanding photoreceptors in a degenerated retina may ease the strain on a microvascular network compromised by diabetes (Arden et al., 2005). It is
important to note that all of these observations are limited by
sample size, due to the rare co-occurrence of RP and diabetes
and by the observational nature of the studies.
Experimental evidence
These clinical observations gave rise to the notion that photoreceptor loss in RP may ameliorate the microvasculature deterioration characteristic of DR by counterbalancing diabetes-induced
retinal hypoxia. To test this hypothesis, de Gooyer and collaborators compared the severity of DR between rhodopsin/ or wildtype controls 5 months following streptozotocin (STZ) exposure,
to model type 1 diabetes. Whereas STZ-treated wild-type mice
showed characteristic features of DR, including reduced retinal
microvascular density and elevated inner retinal hypoxia, STZtreated rhodopsin/ mice did not. Moreover, STZ-associated
upregulation of vascular endothelial growth factor-A (VEGF-A),
a pivotal disease-promoting factor regulated by hypoxia, was attenuated in rhodopsin/ mice. Consistent with these findings,
rhodopsin/ or P23H knock-in transgenics at 5 months and 8
months post STZ injection, respectively, showed decreased capillary atrophy compared to wild-type controls (de Gooyer et al.,
2006a; Sakami et al., 2011). Interestingly, in both strains of mice,
retinal capillary degeneration occurred during the period when
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photoreceptors were still present but was reduced once photoreceptor degeneration occurred. These observations suggest that
primary photoreceptor diseases significantly influence microvasculature health. Although the precise molecular abnormalities
linking the two remain unknown, these experimental findings
appear consistent with the notion that preserving normal photoreceptor physiology could ameliorate microvasculature damage in
diseases such as diabetes (Liu et al., 2016).
The results of the above studies suggest that oxygen consumption by photoreceptors in diabetes could cause pathologic inner
retinal hypoxia, thereby triggering hypoxia-linked gene expression (de Gooyer et al., 2006b). An attractive feature of this model
is that it could also explain the beneficial effects of panretinal
photocoagulation (PRP) on stemming advanced features of DR
(Investigators, 1978) in that laser ablation of photoreceptors
could cause similar reduction of oxygen requirements as RP
(Arden et al., 2005; Graham et al., 2006) (Fig. 1).
Rather than correcting hypoxia, loss of photoreceptors could
improve oxidative stress due to diabetes. Retinal oxidative stress
develops in diabetes due to an imbalance between the production
of reactive oxygen species (ROS) and antioxidant enzymes (Kern,
2017). Though retinal ROS, such as superoxide, accumulates in
multiple retinal layers in diabetes, photoreceptors are the major
source of these molecules as assessed using histochemical and bioluminescence methods. Rhodopsin/ mice have diminished diabetesinduced oxidative stress compared to wild-type controls, and this
finding correlates with reduced induction of inflammatory molecules
such as inducible nitric oxide synthase (iNOS) and intercellular
adhesion molecule-1 (ICAM-1). Collectively, this evidence suggests
that photoreceptors are major contributors to diabetes-induced retinal superoxide and inflammation (Du et al., 2013). However, the
specific molecular abnormalities governing diabetes-induced activation of superoxide generation are unclear. Furthermore, more work is
needed to identify the intermediate steps bridging photoreceptor
oxidative stress to retinal vascular pathology in diabetes.
Energy demands of the photoreceptor in light- and
dark-adapted conditions
As detailed above, although dysregulated photoreceptor physiology
in diabetes is linked to the development of early retinopathy, the
relevant mechanisms are unclear. Here, we provide a brief overview
of the major function of photoreceptor physiology, namely the
transduction of light energy into chemical signals and the energy
costs of this process.
Phototransduction and the visual cycle
Mammalian photoreceptors have the remarkable ability to detect
and reliably transduce light over a wide range of light intensities into
an electrical response that can be relayed to the rest of the visual
system (Arshavsky & Burns, 2012). Rod photoreceptors comprise
nearly 95% of all photoreceptors and mediate dim light (scotopic)
vision. The remaining 5% are cone photoreceptors concentrated in
the central retina and provide high visual acuity and color vision
under bright light (photopic) conditions (Curcio et al., 1990).
Despite their important functional differences, these two types of
photoreceptors share the same principles of phototransduction, the
cellular mechanism of light detection (Kefalov, 2012).
Photoreceptors are characterized by their specialized outer
segments containing membranous discs densely occupied by
phototransduction-related signaling proteins and visual pigments.
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Fig. 1. Protective effects of outer retinal loss due to laser or inherited degenerations on diabetic retinopathy. (A) Wide-field scanning laser ophthalmoscopic image of a patient with
a history of proliferative diabetic retinopathy, treated with panretinal photocoagulation. Seen are laser scars scattered in the retinal periphery (arrowheads) and signs of regression
of fibrovascular disease (arrows). (B) Wide-field image from a patient with retinitis pigmentosa and concomitant type-1 diabetes, showing profound peripheral outer retinal
atrophy and a notable absence of diabetic retinopathy. (C) Optical coherence tomogram showing a macular laser photocoagulation scar in the outer retina (arrowhead) in a
patient with diabetes. (D) Outer retinal scars from peripheral laser photocoagulation in a patient with proliferative diabetic retinopathy (arrowheads). (E) Outer retinal loss in a
patient with retinitis pigmentosa (arrowheads).

As illustrated in Fig. 2A, the visual pigment is formed by the
covalent association of the G-protein-coupled receptor opsin with
the light-sensing visual chromophore 11-cis-retinal (11-cis-RAL),
obtained from Vitamin A (all-trans-ROL) via a process known as
the “visual cycle” (Saari, 2000; Hargrave, 2001). Phototransduction
begins when photon absorption activates visual pigment via isomerization of 11-cis-RAL to all-trans-RAL. This initiates a G-protein
signaling cascade that culminates in cyclic guanosine monophosphate (cGMP) breakdown and consequent closure of cGMPsensitive channels (Arshavsky & Burns, 2012). Reduction in
sodium ion (Na+) and calcium ion (Ca2+) influx through cGMPsensitive channels leads to photoreceptor hyperpolarization. The
associated reduction of glutamate release at the synaptic terminal
signals the quantity of photon absorption to the rest of the visual
system (Arshavsky et al., 2002). The photoresponse persists until
each phototransduction protein becomes deactivated through the
action of one or more regulatory enzymes (Mendez et al., 2000;
Stephen et al., 2008; Anderson et al., 2009).
Comparison of energy requirements in darkness and in light
In light-adapted conditions, photoreceptors are actively engaged
in the phototransduction cascade and visual cycle (Calvert et al.,
2006). In contrast, during strict dark adaptation, these processes
primarily become inactive, allowing cGMP to accumulate within
photoreceptors (Fain et al., 1996). Consequent opening of cGMPsensitive channels allows influx of Na+ and Ca2+ into the outer
segment, which leads to membrane depolarization. Excess Na+ and
Ca2+ must then be extruded by Na+/K+ ATPase and Ca2+ ATPase
pumps in the inner segment (Hagins et al., 1970).
As illustrated in Fig. 2B, significantly more energy is required to
maintain this electrochemical gradient or “dark current” in comparison to any light-dependent photoreceptor activities, including

phototransduction. In fact, energy requirement calculations show a
350% increase in energy consumption in darkness. Specifically, estimated ATP expenditure in a mouse rod photoreceptor amounts to a
total of 9  107 ATP/s in darkness compared to only 2  107 ATP/s
in bright illumination (Okawa et al., 2008). This disparity primarily
arises from ATP-dependent ion pumping to maintain the dark
current. Na+/K+ ATPase utilizes about 50% of total energy requirements in darkness (5.7  107 ATP/s), of which 70% is directed
toward maintenance of the dark current. In contrast, Na+/K+
ATPase only requires 15% of energy in light, 0% of which is utilized
for dark current. The majority of the remaining energy expenditure
in darkness is attributed to Ca2+ ATPase activity (3  107 ATP/s).
Although photoreceptors release more glutamate in the dark due to
depolarization, glutamate synthesis and recycling only consume less
than 4  106 ATP/s (Wong-Riley, 2010).
In bright illumination, phototransduction involves multiple
steps utilizing guanosine triphosphate (GTP) and ATP; however,
these requirements are minimal relative to those in darkness.
GTPase activity associated with transducin utilizes less than 3 
106 ATP/s in rods and cGMP turnover spends about 2  106
ATP/s. Likewise, there is negligible expenditure on the regulatory
enzymes that terminate the photoresponse. Ca2+ channels also
consume relatively little energy in bright illumination (WongRiley, 2010). Thus, it becomes readily apparent how total energy
consumption in bright light is less than a quarter of that in the dark.
Retinal energy supply and metabolic flux
Photoreceptors are known to have extraordinary energy demands
and a high density of mitochondria; however, their fuel sources are
not yet clearly delineated. Glucose serves as an important source of
energy for photoreceptors, like other neurons in the central nervous system. Similar to metabolically demanding tumors, the retina
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Fig. 2. Energy requirements of photoreceptors in light and dark. Schematic of photoreceptor and adjacent retinal pigment epithelium engaged in activities corresponding to light
(A) and dark (B) conditions. The main ATP-consuming processes for each condition are outlined. ATP, adenosine triphosphate; GTP, guanosine triphosphate; cGMP, cyclic
guanosine monophosphate; s, second; RPE, retinal pigment epithelium; ECF, extracellular fluid; hv, light; 11-cis-RAL, 11-cis-retinal; 11-cis-ROL, 11-cis-retinol; ATRA, all-trans-retinal;
ATRO, all-trans-retinol; Na+, sodium ion; Ca2+, calcium ion; PDE, phosphodiesterase; CB, cell body; Syn, synaptic terminal.

metabolizes the majority of its glucose into lactate via aerobic
glycolysis rather than through oxidative phosphorylation for
ATP production (Warburg et al., 1927; Joyal et al., 2018). Yet in

pig retinal explants, only 20% of glucose is oxidized, suggesting that
the retina uses alternate fuels for oxidative phosphorylation (Wang
et al., 1997). Recently, palmitate was shown to be a possible fuel
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substrate for mitochondrial energy production in photoreceptors
(Joyal et al., 2016). Furthermore, mechanisms accounting for fuel
partitioning in photoreceptors are poorly understood. Weak
coupling of ATP synthesis and respiration in photoreceptors
compared to other tissues suggests that photoreceptor energy
production does not respond directly to energy demand but rather
may fall under the control of photoreceptor signaling. Phototransduction, for instance, elevates citrate production by simultaneously
increasing flux through citrate and decreasing flux through citric
acid cycle intermediates (Du et al., 2016). This may occur via
phototransduction-mediated depletion of calcium surrounding
mitochondria clustered at the junction of outer and inner segments,
thereby impacting the distribution of metabolites between matrix
and cytosol (Krizaj & Copenhagen, 2002; Glancy & Balaban, 2012;
Llorente-Folch et al., 2015). The increased citrate can then serve as
a substrate to produce nicotinamide adenine dinucleotide phosphate (NADPH) required for the reduction and detoxification of
all-trans-RAL generated by light-induced bleaching of rhodopsin
(Adler et al., 2014). Among other metabolic changes, phototransduction also decreases metabolic flux through glycolysis and influences concentrations of 50 -GMP, ribose-5-phosphate, ketone
bodies, and purines. Significantly, transcriptional coupling mechanisms also ensure precise matching of energy production with
energy consumption (Du et al., 2016).
Oxygen consumption by photoreceptors
In order to produce ATP, photoreceptors require a blood supply of
glucose and oxygen. Given the avascularity of the photoreceptor
layers, photoreceptors normally function at low partial oxygen
pressure (pO2). Light-adapted photoreceptors primarily extract
oxygen from the choroidal circulation, allowing their local pO2 to
reach up to 40 mmHg. However, the remarkably intense activity
and oxygen consumption of photoreceptors in darkness reduce
their surrounding minimum pO2 tension to zero, triggering supplemental oxygen to be supplied from the central retinal artery and
subsequently resulting in extension of a low oxygen tension environment to the inner retina (Linsenmeier, 1986; Braun et al., 1995).
Such a model raises the concern that in disease states with suboptimal oxygen supply, pathologic hypoxia may develop in the
inner portions of the retina when rod photoreceptors operate at
maximum activity in darkness. To test whether such a concern is
valid, longitudinal blood flow and oxygen measurements obtained
with visible-optical coherence tomography were used to assess
inner retinal oxygen metabolism (IRMO2) in murine models of
early type 1 diabetes. Notably, these analyses revealed alterations in
IRMO2 prior to detectable retinal vascular complications in early
diabetes (Liu et al., 2017). Although the mechanism underlying
changes in IRMO2 are obscure, these findings suggest that abnormalities in oxygen metabolism precede and may contribute to
DR. In line with this notion, oxygen supplementation in patients
with diabetes reverses visual deficits typical of diabetic neuroretinopathy, measured using psychophysical and electrophysiological
tests. Therefore, both preclinical and clinical evidence highly suggest that insufficient oxygen supply to the neural retina is an
important contributor to vision loss in diabetes (Harris et al.,
1996; Dean et al., 1997; Drasdo et al., 2002).
Manipulating light exposure as a therapy for DR
Although the evidence for retinal hypoxia in DR is strong, the
reasons for its development are not so clear. One widely accepted
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mechanism involves hyperglycemia-induced damage of retinal
microvasculature in early diabetes (Arden et al., 2005). To counteract such losses in oxygen supply due to microvessel compromise
in diabetes, Dr. Arden proposed that reducing retinal oxygen
demand could ease the strain on its vascular network. Since retinal
ATP and oxygen use is higher in the dark than in light due to the
dark current, as detailed above, he expected that retinal hypoxic
stress in diabetes would be intensified by dark adaptation. Conversely, lowering rod photoreceptor dark current—by pharmacologic means or by use of continuous low-level illumination—would
prevent DR. These predictions culminated in Arden’s hypothesis
that having people with diabetes sleep in light levels of 1–10 cd/m2
would allow sufficient light to pass through the eyelids to prevent
full dark adaptation, thereby providing beneficial effects for DR
(Arden et al., 2005).
Clinical evidence for light therapy in DR
Arden’s hypothesis was tested in several clinical trials that evaluated the efficacy of nighttime low-level light exposure on reduction
of DR. Two short-term, early-phase prospective clinical trials
showed improvement in DR measures in patients who wore
custom-designed light masks while sleeping (Arden et al., 2010,
2011). However, in the follow-up phase 3 trial (CLEOPATRA),
these light masks failed to show efficacy in DR, using reduction in
preexisting noncentral diabetic macular edema as the primary end
point (Sivaprasad et al., 2018). Likewise, in a STZ-rodent study,
constant light exposure did not alleviate neuroretinal abnormalities
during early stages of diabetes (Kur et al., 2016). Moreover, the
CLEOPATRA trial noted challenges with wearing of the light
masks during sleep, concluding this may not be a sustainable or
effective option (Sivaprasad et al., 2018). Nevertheless, other clinical trials of light masks to prevent dark adaptation in DR are
ongoing, including the Lahey Light II trial (LCID Study Number
2015-020), which is investigating a modified 520 μm LED light
mask to prevent dark adaptation in refractory diabetic macular
edema (Okada & Chhablani, 2018). Collectively, given the conflicting evidence from preclinical and clinical studies, the roles that
light and darkness have on DR remain controversial.
Effects of light manipulation in experimental DR
Considering these negative findings, our group recently investigated the prediction that light deprivation, or prolonged dark
adaptation, will worsen DR due to increased energy consumption
in darkness. We shielded diabetic mice from light exposure and
measured retinopathy outcomes. Unexpectedly, we found that light
deprivation prevented the development of diabetes-induced delays
in visual responses assessed by full-field electroretinography in
both tested models of experimental diabetes: db/db mice, a type
2 diabetes model, and in STZ-treated mice, a type 1 diabetes model.
Similarly, two mouse mutants with impaired rod responses to
photostimulation—Gnat1/ and Rpe65/—were also protected
from DR (Thebeau et al., 2020). These findings were consistent
with an independent study in STZ-treated Gnat1/ mice, demonstrating that they showed no increase in capillary atrophy,
leukostasis, or inner retinal barrier loss in diabetes, compared to
nondiabetic counterparts. Notably, the authors of that study
observed persistent albumin leakage into the outer retina in diabetic Gnat1/ mice (Liu et al., 2019). Collectively, these observations in light-deprived animals and models of Gnat1 loss and Rpe65
loss suggest that light-induced signaling from photoreceptors is
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required for the pathogenesis of DR. Yet our results introduce an
apparent mechanistic paradox, since light-deprived retinas require
more energy than light-exposed retinas and add another level of
complexity to the issue of light exposure and its effects on DR.
Mechanistic implications
The protective effects of light deprivation and phototransduction
ablation clearly diverge from Arden’s prediction that continuous
light exposure would ameliorate DR by reducing the metabolic
demands of dark adaptation. His prediction originated from a
widely held view that diabetes leads to a primary vasculopathy,
resulting in insufficient energy supply to the neural retina. An
alternative view, in which diabetes causes a primary neuropathy
of the retina with subsequent effects on the retinal vasculature
(Honasoge et al., 2019; Thebeau et al., 2020), permits exploration
of novel mechanisms by which light deprivation could inhibit the
development of DR, which we will now discuss.
First, how does light-dependent signaling affect fuel substrate
selection in photoreceptors experiencing chronic hyperglycemia
during early diabetes? Notably, phototransduction itself drives
metabolic flux in mouse retina, raising the possibility that it may
also influence fuel substrate selection (Du et al., 2016). While
aerobic glycolysis is a major metabolic pathway in photoreceptors,
it is now becoming evident that the retina also uses fatty acid
ß-oxidation for energy metabolism. As evidence, retinas from mice
with deletion of the gene encoding very low-density lipoprotein
receptor (Vldlr/) show reduced retinal glucose uptake due to
suppressed expression of the Glut1 transporter from high levels of
circulating lipids. This suppression was mediated by the lipid
sensor–free fatty acid receptor 1 (Ffar1), which is necessary for
fatty acid uptake into photoreceptors. Moreover, disruption of
Ffar1 caused abnormal retinal neovascularization, suggesting this
metabolic pathway could be relevant to neovascular retinal disease,
such as DR (Joyal et al., 2016). The presence of this interplay
between glucose and lipid metabolism suggests that the retina is
capable of adapting its fuel utilization to improve metabolic efficiency and match nutrient availability. This strategy is also
employed by other metabolically demanding tissues in response
to environmental stress in order to confer survival advantages
(Joyal et al., 2018).
Clinical evidence implicating fatty acid ß-oxidation in DR has
emerged from two large scale clinical trials (FIELD and ACCORD
Eye studies), which found that fenofibrate-induced activation of
PPARα, a nuclear receptor that modulates lipoprotein lipase
expression and triglyceride metabolism, reduced the progression
of DR by 30–40% (Keech et al., 2007; Group et al., 2010). This was
supported by rodent models of pathological retinal angiogenesis, in
which fenofibrate reduced retinal neovascularization and retinal
vascular leakage (Chen et al., 2013). Although the precise mechanisms accounting for the beneficial effects of fenofibrate in the
diabetic retina remain unclear, the drug could promote a fuel
switch to fatty acids in photoreceptors to correct diabetesassociated retinal energy deficit and subsequent neural dysfunction. This understudied concept will require the further exploration
of other control mechanisms for fuel substrate selection and the
interplay between glucose and lipid metabolism in photoreceptor
cells.
Beyond their newly identified roles in retinal metabolism, lipids
also serve as the fundamental unit of photosensitive discs in photoreceptor outer segment. As these lipids are vulnerable to damage
from light and oxidation, decreasing light exposure may reduce
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levels of oxidative damage to lipids in the outer segment of photoreceptors (Fu et al., 2020). The detrimental effects of light-induced
lipid damage were elucidated in a study exposing rodents to constant light. In this study, light-induced oxidative stress reduced
retinal levels of a critical fatty acid in the adult human retina,
docosahexaenoic acid. Consequently, this led to changes in cellular
membrane composition and rigidity, a phenomenon known to
affect cellular metabolism in other cell types (Habib et al., 1987;
Benedetto & Contin, 2019). Further studies on light-induced oxidative damage to photoreceptor lipids may provide novel insights
into the role of retinal oxidative stress in DR.
In addition to modulating fuel substrate selection, increased
energy demands confronting diabetic photoreceptors in darkadapted conditions could potentially confer advantageous adaptations in metabolism. For instance, increased demand for ATP in
darkness may give rise to mitochondrial expansion and increased
oxidative capacity, resembling the effects seen after exercise on
skeletal muscle (Meinild Lundby et al., 2018). Moreover, dark
exposure could have effects on improving retinal insulin sensitivity,
which is reduced in diabetes (Reiter et al., 2006).
Conceivably, dysfunctional photoreceptors may also participate
in the non-cell autonomous progression of DR by disturbing the
other retinal cell types with which they directly or indirectly
communicate. Müller cells—the principal glia of the retina—
respond to the metabolic demands of retinal neurons by regulating
blood flow through their dependent vessels, a process referred to as
neurovascular coupling or functional hyperemia (Metea & Newman, 2006). Specifically, in response to neural stimuli, Müller cells
release vasoactive substances, such as nitric oxide (Newman, 2013).
Although light stimulates vasodilation in healthy retina, patients
with diabetes show decreased vascular reactivity to light (Berkowitz
et al., 2015). Subsequent rodent studies attributed the reduced
vascular reactivity in diabetes, in part, to elevated local nitric oxide
concentration caused by a diabetes-induced increase in Müller cell
expression of inducible nitric oxide. Restoration of neurovascular
coupling in diabetic rodents occurred following treatment with
aminoguanidine, an inhibitor of inducible nitric oxide (Mishra &
Newman, 2010, 2011). As diabetic patients show signs of compromised neurovascular coupling as evidenced by reduced lightinduced vascular reactivity, perhaps, a reduction in light-induced
photoreceptor signaling could reduce stress on this system.
In addition to neuroglial interactions, photoreceptors may also
communicate with leukocytes through release of proinflammatory
cytokines in diabetes (Du et al., 2013; Kern, 2017). Interestingly,
loss of phototransduction signaling in Gnat1/ mice is associated with reduced diabetes-induced release of proinflammatory
proteins, leukostasis, and leukocyte-mediated cytotoxicity to endothelial cells (Liu et al., 2019). This suggests that phototransduction,
a process unique to photoreceptors, plays a significant role in the
development of an inflammatory state and potentially, the eventual
development of DR.
Visual cycle inhibition in DR
Clear limitations to strategies involving light modulation in the
treatment of DR include the poor feasibility of keeping patients in
prolonged low-light conditions and unintended effects on circadian cycles. Therefore, pharmacologic visual cycle inhibition
represents another possible intervention for DR that targets photoreceptor metabolic physiology. In STZ-treated mice, systemic treatment with retinylamine—a retinoid that inhibits the critical visual
cycle enzyme RPE65—significantly reduces diabetes-induced
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oxidative stress, induction of inflammatory proteins, capillary permeability, and capillary degeneration (Liu et al., 2015). Slowing of the
visual cycle could improve DR by several mechanisms. First, slowed
visual cycle activity reduces 11-cis and all-trans-RAL levels in photoreceptor outer segments, thus reducing formation of precursors of
bisretinoid toxins, such as A2E. Likewise, low all-trans-RAL levels
also reduce the frequency of lipid peroxidation and generation of
ROS. Second, light-dependent photoreceptor signaling could be
permissive for DR development, as suggested by our own experience
with Gnat1/ and Rpe65/ mice (Thebeau et al., 2020). Therefore,
visual cycle inhibition might reduce these permissive signals. Third,
despite an absence of light-dependent photoreceptor signaling, constitutive activity by visual chromophore-free opsin (apo-opsin) also
prevents full dark adaptation, thereby reducing the metabolic
demand as shown using manganese-assisted magnetic resonance
imaging and oxygen tension measurements (Kubota et al., 2019).
The relative contributions of decreased visual chromophore-derived
toxin production, light-dependent photoreceptor signaling, and
metabolic demands via apo-opsin signaling remain to be determined.
The promising results of visual cycle inhibition in diabetic
animal models led to clinical testing of emixustat, the first clinical
candidate in a class of nonretinoid, small-molecule compounds
that reversibly inhibits the same target as retinylamine, RPE65.
Early-phase clinical trials suggested that emixustat may reduce
progression of DR in animal models. Currently, phase 3 clinical
trials testing its efficacy in the treatment of DR, albeit in later stages
of the disease, are ongoing (Kubota et al., 2019). As emixustat
inhibits the visual cycle, potential adverse consequences on vision
by emixustat treatment should be considered. Nyctalopia and
dyschromatopsia were reported in emixustat clinical trials, consistent with emixustat’s mechanism of action (Kubota et al., 2014,
2019). While emixustat shares the ability of retinylamine to inhibit
RPE65, it also has the capacity to complex with and sequester alltrans-RAL via a condensation reaction. This may effectively reduce
toxicity associated with excess free all-trans-RAL and raises the
possibility that emixustat might operate in multiple ways to correct
DR (Kubota et al., 2020).
Conclusion
DR is an important contributor to vision loss worldwide, and its
prevalence is increasing. The clinical manifestations of the disease
have historically been measured by observing characteristic vascular lesions. However, evidence from many groups in both clinical
and preclinical settings strongly suggests that many retinal cell
types are affected by diabetes, and perhaps, the initial insult could
be a retinal neuropathy. Moreover, photoreceptors are clearly
significant contributors to early retinal disease in diabetes. Stemming from observations of photoreceptor dysfunction in diabetes,
modulation of phototransduction and inhibition of the visual cycle
have emerged as novel modes of therapy for DR. However, the
nature of putative contributions that the photoreceptor response to
light may have on DR pathogenesis and therapy remains highly
controversial and is an area of active and exciting investigation.
Diabetes may impact several aspects of photoreceptor physiology
in understudied ways, including fuel substrate selection, lipid oxidation, mitochondrial adaptation, and neurovascular coupling. It
may also impact very well-characterized states of retinal pathophysiology, such as inflammatory responses, hypoxic drive, and
oxidative stress. Moving forward, implementation of conditional
genetic knockout or viral delivery strategies may elucidate how
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specific molecular perturbations within photoreceptors could
impact any or all of these disease processes. In addition, temporal
molecular profiling of photoreceptors over the extent of diabetes
may reveal molecular abnormalities driving or marking the development and progression of DR. Ultimately, insights into photoreceptor physiology in DR may yield novel therapies that modulate
the photoreceptor response to light to ameliorate diabetic retinal
disease while maintaining intact vision.
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